RAPT Therapeutics, Inc. (RAPT)
RAPT moved a median of -0.02% 30 minutes after news, and 0.00% by the close. How RAPT actually reacts to news — the realized, point-in-time move the market made, measured across 261 labeled events over the last three years with zero look-ahead.
RAPT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.01% | 51% | 234 |
| 30-min | -0.02% | 48% | 234 |
| 60-min | 0.00% | 49% | 234 |
| to close | 0.00% | 50% | 235 |
| Middle 50% of RAPT reactions | -1.39% to +1.03% |
|---|---|
| Median reaction (30-min) | -0.02% |
| Measured reactions | 261 |
Half of all RAPT Therapeutics, Inc. news events land between -1.39% and +1.03% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How RAPT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 15 | -4.03% | 20% | -2.88% |
| Analyst downgrades | 50 | +0.01% | 54% | +0.10% |
| Coverage initiations | 22 | -1.31% | 27% | +0.21% |
| Rating reiterations | 41 | -0.07% | 37% | -1.14% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how RAPT ranks against every other measured name →
That’s how RAPT usually reacts — get an email when it moves on news →Email me when RAPT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RAPT's baseline. Nothing else.
Recent RAPT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G RAPT Therapeutics, Inc. | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form EFFECT RAPT Therapeutics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Form 8-K RAPT Therapeutics, Inc. For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM RAPT Therapeutics, Inc. | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form S-8 POS RAPT Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Halper Sadeh LLC is Investigating Whether RAPT, CTGO, TBN, FOLD are Obtaining Fair Deals for their Shareholders | Press release | GlobeNewswire | +0.03% | +0.17% | |
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR) | Press release | GlobeNewswire | -0.02% | +0.09% | |
| Halper Sadeh LLC Reminds Shareholders of JHG, FOLD, RAPT of the Firm’s Investigations | Press release | GlobeNewswire | -0.02% | +0.09% | |
| Halper Sadeh LLC Reminds Shareholders of RAPT, PEN, CVGW, FONR of the Firm’s Investigations | Press release | GlobeNewswire | -0.02% | +0.09% | |
| Halper Sadeh LLC Encourages NATH, PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights | Press release | GlobeNewswire | -0.04% | -0.09% | |
| Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights | Press release | GlobeNewswire | +0.00% | -0.04% | |
| Form 8-K RAPT Therapeutics, Inc. For: Jan 19 | SEC filing · Form 8-K | SEC EDGAR | +0.11% | +0.19% | |
| RAPT Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of RAPT Therapeutics, Inc. is Fair to Shareholders | Press release | Business Wire | +0.11% | +0.19% | |
| Form 8-K RAPT Therapeutics, Inc. For: Jan 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.00% | |
| RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +0.18% | -3.76% | |
| Form 8-K RAPT Therapeutics, Inc. For: Nov 24 | SEC filing · Form 8-K | SEC EDGAR | — | +0.00% | |
| Form 10-Q RAPT Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.02% | +2.72% | |
| Form 8-K RAPT Therapeutics, Inc. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +0.02% | +2.72% | |
| RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights | Press release | GlobeNewswire | +0.02% | +2.72% | |
| RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences | Press release | GlobeNewswire | -0.09% | -1.46% | |
| RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies | Press release | GlobeNewswire | -1.02% | +0.33% | |
| Form 8-K RAPT Therapeutics, Inc. For: Oct 21 | SEC filing · Form 8-K | SEC EDGAR | -0.23% | -0.33% | |
| RAPT Therapeutics Announces Pricing of Public Offering of Common Stock | Press release | GlobeNewswire | -5.26% | -8.56% | |
| RAPT Therapeutics Announces Proposed Public Offering of Common Stock | Press release | GlobeNewswire | -5.26% | -8.56% | |
| Form 8-K RAPT Therapeutics, Inc. For: Oct 20 | SEC filing · Form 8-K | SEC EDGAR | -7.98% | -19.83% | |
| RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria | Press release | GlobeNewswire | -7.98% | -19.83% | |
| RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU) | Press release | GlobeNewswire | -7.98% | -19.83% | |
| RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy | Press release | GlobeNewswire | +1.82% | -0.78% | |
| RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences | Press release | GlobeNewswire | -0.27% | +3.28% | |
| Form 10-Q RAPT Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.37% | +1.08% | |
| Form 8-K RAPT Therapeutics, Inc. For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -2.37% | +1.08% | |
| RAPT Therapeutics Reports Second Quarter 2025 Financial Results | Press release | GlobeNewswire | -2.37% | +1.08% | |
| Form 8-K RAPT Therapeutics, Inc. For: Jul 08 | SEC filing · Form 8-K | SEC EDGAR | +0.74% | +4.84% | |
| Form 8-K RAPT Therapeutics, Inc. For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | -2.82% | +0.00% | |
| RAPT Therapeutics Names Two Industry Veterans to its Board of Directors | Press release | GlobeNewswire | -2.82% | +0.00% | |
| Form S-8 RAPT Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | -2.13% | -0.93% | |
| Form 8-K RAPT Therapeutics, Inc. For: Jun 13 | SEC filing · Form 8-K | SEC EDGAR | -3.13% | +0.95% | |
| RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split | Press release | GlobeNewswire | -5.61% | -2.80% | |
| Form 8-K RAPT Therapeutics, Inc. For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | +0.85% | +0.85% | |
| RAPT Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +2.97% | +0.99% | |
| Form 8-K RAPT Therapeutics, Inc. For: May 29 | SEC filing · Form 8-K | SEC EDGAR | -2.01% | -2.71% | |
| Form 8-K RAPT Therapeutics, Inc. For: May 21 | SEC filing · Form 8-K | SEC EDGAR | -0.21% | -3.09% | |
| Form 10-Q RAPT Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.06% | -4.69% | |
| Form 8-K RAPT Therapeutics, Inc. For: May 08 | SEC filing · Form 8-K | SEC EDGAR | +0.06% | -4.69% | |
| RAPT Therapeutics Reports First Quarter 2025 Financial Results | Press release | GlobeNewswire | +0.06% | -4.69% | |
| RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development | Press release | GlobeNewswire | +0.74% | -4.88% | |
| Form ARS RAPT Therapeutics, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.74% | -4.88% | |
| Form DEF 14A RAPT Therapeutics, Inc. For: May 29 | SEC filing · Form DEF | SEC EDGAR | +4.34% | +8.94% | |
| Form DEFA14A RAPT Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +4.34% | +8.94% | |
| Form PRE 14A RAPT Therapeutics, Inc. For: Apr 04 | SEC filing · Form PRE | SEC EDGAR | -3.92% | +2.94% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RAPT section they belong to.
Where else RAPT is measured.
RAPT earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is RAPT Therapeutics, Inc.'s median reaction calculated?
Every labeled RAPT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 261 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of RAPT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RAPT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.